Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 683 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Dermatitis (Eczema) Clear all
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 1 Interventional

Topical ENS-002 for Atopic Dermatitis in Adults

NCT06469385
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema
Interventions
ENS-002
Biological
Lead sponsor
Concerto Biosciences
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Hollywood, Florida • Beverly, Massachusetts • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

NCT06181435
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Scottsdale, Arizona • Tucson, Arizona • Lomita, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Not applicable Interventional

Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients

NCT02713035
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
Self help intervention
Behavioral
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
4 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

NCT06810050
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
12 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Fremont, California • Manhattan Beach, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals

NCT00001760
View directory record Official record
Conditions
Atopic Dermatitis, Healthy, Mastocytosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2007 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
View directory record Official record
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

NCT01652885
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Fremont, California • San Diego, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sweat and Gas Sensor for Healthy Skin and Atopic Dermatitis

NCT03874039
View directory record Official record
Conditions
Healthy Adults, Atopic Dermatitis, Wearables, Sweat Sensor, Gas Sensor
Interventions
Gas sensor, Sweat Sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

NCT05034822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 11 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Anaheim, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

NCT03725722
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • Encino, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 6, 2026, 4:55 PM EDT
Not listed No phase listed Observational

Systemic Therapies for Pediatric Atopic Dermatitis

NCT01447381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

NCT04668066
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-07242813, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Anaheim, California • Fountain Valley, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sebum Collection and Skin Barrier Function Analysis

NCT03112876
View directory record Official record
Conditions
Smoking, Acne, Atopic Dermatitis, Aging
Interventions
Skin Surface Lipid Collection and Skin Barrier Function
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

NCT03915496
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-04965842 200 mg, PF-04965842 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Largo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 6, 2026, 4:55 PM EDT
Completed No phase listed Observational

Clinical and Immunological Evaluation of Children With Allergies

NCT00102570
View directory record Official record
Conditions
Hypersensitivity, Immediate
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 19 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT05158023
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo Comparator, ASLAN004
Drug · Biological
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional

Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

NCT00985894
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Online Teledermatology Care, Conventional in Office Care
Other
Lead sponsor
University of California, Davis
Other
Eligibility
4 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study of Patients With Dermatologic Disease

NCT07748169
View directory record Official record
Conditions
Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
2,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 4:55 PM EDT